Alzubi, Mohammad A.
Turner, Tia H.
Olex, Amy L.
Sohal, Sahib S.
Tobin, Nicholas P.
Recio, Susana G.
Bergh, Jonas
Hatschek, Thomas
Parker, Joel S.
Sartorius, Carol A.
Perou, Charles M.
Dozmorov, Mikhail G.
Harrell, J. Chuck http://orcid.org/0000-0003-3541-8418
Funding for this research was provided by:
METAvivor (2015 Grant)
National Cancer Institute (P30 CA016059, P50-CA58223, RO1-CA148761, R01-CA195754)
Breast Cancer Research Foundation (2015 Grant)
National Center for Advancing Translational Sciences (UL1TR002649)
Article History
Received: 17 September 2018
Accepted: 19 February 2019
First Online: 6 March 2019
Ethics approval
: All animal procedures were approved by the Virginia Commonwealth University and University of North Carolina Institutional Animal Care and Use Committees.
: Non-identifiable patient data was utilized in these studies.
: C.M.P is an equity stockholder, consultant, and Board of Director Member of BioClassifier LLC. C.M.P is also listed as an inventor on patent applications for the Breast PAM50 Subtyping assay. The other authors declare no potential conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.